Application of nickelin-like protein in marker for predicting carotid plaque occurrence risk of type 2 diabetes mellitus

By measuring the serum level of nickel lacetin-like protein (Metrnl) and using it as a marker, the prediction problem of carotid plaque risk in patients with type 2 diabetes was solved, and effective prediction of carotid plaque in patients with T2DM was achieved, which improved the Early diagnosis and prognosis.

CN118937684AInactive Publication Date: 2024-11-12AFFILIATED HOSPITAL OF JIANGSU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410990375.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art lacks effective markers for predicting the risk of carotid artery plaque in patients with type 2 diabetes, affecting the implementation of early diagnosis and intervention measures.

Method used

Using nickel lacetin-like protein (Metrnl) as a marker for predicting the risk of carotid plaque in type 2 diabetes, the patient's risk of carotid plaque is judged by measuring its serum levels. A kit or an in vitro diagnostic system is provided for detection. .

Benefits of technology

The significant increase in serum levels of Metrnl is related to carotid artery plaque formation in patients with type 2 diabetes. It has good predictive value as a predictive marker and can effectively judge the risk of carotid artery plaque in patients with T2DM and improve early diagnosis and prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937684A_ABST
    Figure CN118937684A_ABST
Patent Text Reader

Abstract

The invention provides an application of nickel-like protein in a marker for predicting the risk of occurrence of carotid plaques of type 2 diabetes mellitus, and an application of nickel-like protein in a marker for acquiring information for predicting the risk of occurrence of carotid plaques of type 2 diabetes mellitus. The invention relates to application of nickelin-like protein in preparation of a product for predicting the carotid plaque occurrence risk of type 2 diabetes mellitus. The product is a kit, the kit at least comprises a reagent for detecting a marker used for predicting the occurrence risk of carotid plaques suffering from type 2 diabetes, and the marker is nickel-like protein. Compared with a type 2 diabetes mellitus sample without carotid plaque, if the nickel-like protein serum level in the subject sample is obviously increased, the occurrence risk of the type 2 diabetes mellitus combined with the carotid plaque of the subject is judged to be high, and the nickel-like protein is used as a marker for predicting the occurrence risk of the carotid plaque of the type 2 diabetes mellitus and is used as a marker for predicting the occurrence risk of the carotid plaque of the type 2 diabetes mellitus. And the method has a good prediction value for the combined carotid plaque of the T2DM patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of Meteorin-like protein as a marker for predicting the risk of carotid artery plaque in type 2 diabetes. Background Art

[0002] In recent years, with the aging of the population and changes in lifestyle, the incidence of diabetes has continued to rise worldwide. Poor control of blood sugar, blood lipids, and blood pressure can lead to a series of diabetic complications, which are mainly divided into microvascular (nephropathy, retinopathy, and neuropathy) and macrovascular complications. In recent years, cardiovascular disease has gradually become the main cause of death in diabetic patients, accounting for more than half of the mortality rate in diabetic patients. Atherosclerosis (AS) plays a key role in the occurrence of cardiovascular disease, and it is the main pathological basis for macrovascular complications of diabetes. AS is a progressive inflammatory process, in which lipid accumulation is a key factor in the early stage of the disease. Under the influence of multiple factors such as lipid metabolism disorders, hypertension, and insulin resistance (IR), low-density lipoprotein (LDL) enters the intima of the tube wall through the damaged endothelium and is oxidized and modified into oxidized low-density lipoprotein (ox-LDL). Ox-LDL stimulates endothelial cells to cause inflammatory responses, resulting in increased expression of chemotactic proteins, attracting macrophages to recruit and infiltrate under the intima. Then macrophages engulf ox-LDL and become foam cells to form the earliest atherosclerotic lesions. CIMT thickening often indicates the formation of carotid plaques, which can reflect the systemic AS and are closely related to the occurrence of cardiovascular and cerebrovascular events. Therefore, finding objective indicators for early diagnosis of carotid atherosclerosis and taking intervention measures are crucial to improve the prognosis of patients with T2DM.

[0003] Meteorin-like protein (Metrnl) belongs to the family of proteins of the neurotrophic regulator Meteorin. It consists of 311 amino acids encoded by 936 base pairs. The Metrnl gene is located in the region of mouse chromosome 11qE2 and human chromosome 17q25.3. Studies have shown that Metrnl is the only gene at the end of the q arm of chromosome 17. It may regulate the clinical phenotype of a rare disease called Mild ring 17 syndrome, which is clinically manifested as mental retardation, growth retardation, etc. It is worth noting that 17q25.3 is a susceptibility site for cardiovascular disease. In 2012, Jorgensen et al. studied the role of Metrnl in the nervous system. In isolated dorsal root ganglion cultures, it was observed that Metrnl promoted axon growth in a dose-dependent manner. In rat subventricular zone explants, Metrnl intervention can lead to a significant increase in neuroblast migration. These results indicate that Metrnl contributes to the remodeling and repair of neural circuits. In addition, deaf guinea pigs treated with Metrnl showed significant therapeutic effects on the electrical reactivity of auditory neurons, and the number of surviving spiral ganglion neurons was significantly higher than that of the control group, indicating that Metrnl also has a neuroprotective effect. Therefore, Metrnl was originally considered to be a neurotrophic factor. In 2014, Li et al. identified Metrnl as a new adipokine through gene array and bioinformatics analysis. In the same year, Rao et al. proposed that Metrnl is a circulating factor secreted after muscle exercise and cold stimulation of adipose tissue. Increased expression of Metrnl can significantly stimulate eosinophil-dependent IL-4 expression and promote selective activation of adipose tissue macrophages, thereby promoting the expression of subcutaneous and visceral brown / beige fat thermogenic and anti-inflammatory genes, stimulating energy consumption and improving glucose tolerance. In a controlled study, Liu et al. found that serum Metrnl levels were significantly reduced in patients with metabolic associated fatty liver disease (MAFLD). As serum Metrnl levels increased, the incidence of MAFLD showed a downward trend. This suggests that Metrnl may be a protective factor associated with the pathogenesis of MAFLD. Internal carotid artery plaques are most commonly found at the carotid bifurcation and are an indicator of AS. Their presence indicates that the AS process is ongoing. Carotid artery plaques have been shown to be an independent predictor of future cardiovascular risk. At present, there are few studies on the relationship between serum Metrnl levels and carotid artery plaques in patients with T2DM at home and abroad. Summary of the invention

[0004] In response to the above technical problems, the present invention provides a use of a Meteorin-like protein as a marker for predicting the risk of carotid artery plaques in type 2 diabetes. An elevated serum level of Metrnl, a Meteorin-like protein, is a risk factor for carotid artery plaque formation in patients with type 2 diabetes (T2DM), and has a good predictive value for the risk of T2DM patients developing carotid artery plaques.

[0005] The present invention achieves the above technical objectives through the following technical means.

[0006] A marker for predicting the risk of carotid artery plaque in type 2 diabetes, wherein the marker is Meteorin-like (Metrnl). The Meteorin-like protein (Metrnl) is a member of the Meteorin homologous family of neurotrophic regulatory factors, and is composed of 311 amino acids encoded by 936 base pairs. The Meteorin-like protein (Metrnl) gene is located in the region of mouse chromosome 11qE2 and human chromosome 17q25.3.

[0007] Use of Metrnl as a marker for predicting the risk of carotid artery plaque in type 2 diabetes.

[0008] Use of Meteorin-like protein in obtaining markers for predicting the risk of carotid artery plaque occurrence in type 2 diabetes.

[0009] Use of Meteorin-like protein in the preparation of a product for predicting the risk of carotid artery plaque occurrence in type 2 diabetes.

[0010] In the above scheme, the product includes a kit, or an in vitro diagnostic system or device.

[0011] Furthermore, the product is a kit, which at least includes a reagent for detecting a marker for predicting the risk of carotid artery plaque in type 2 diabetes, and the marker is a Meteorin-like protein.

[0012] In the above scheme, if the serum level of Meteorin-like protein in the subject's sample is significantly increased compared with the sample of type 2 diabetes without carotid artery plaque, it is judged that the subject has a high risk of developing type 2 diabetes combined with carotid artery plaque.

[0013] Compared with the prior art, the present invention has the following beneficial effects:

[0014] Elevated serum levels of Metrnl are a risk factor for carotid plaque formation in patients with T2DM, indicating that Metrnl plays a potential role in the formation and development of carotid plaques in patients with T2DM. As a marker for predicting the risk of carotid plaques in type 2 diabetes, Metrnl has a good predictive value for T2DM patients with carotid plaques. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 : Comparison of serum metrnl levels between normal control group and T2DM group;

[0016] Figure 2 : Comparison of serum Metrnl levels between T2DM subjects with and without carotid plaques;

[0017] Figure 3 : ROC curve of Metrnl in predicting the occurrence of carotid artery plaque in patients with T2DM. DETAILED DESCRIPTION

[0018] The embodiments of the present invention are described in detail below in conjunction with the accompanying drawings, which are intended to be used to explain the present invention and should not be construed as limiting the present invention. The experimental methods used in the following embodiments are conventional methods unless otherwise specified; the reagents, materials, etc. used in the following embodiments are all commercially available unless otherwise specified.

[0019] The marker for predicting the risk of carotid artery plaque in type 2 diabetes mellitus according to the present invention is Meteorin-like protein (Metrnl).

[0020] Use of Metrnl as a marker for predicting the risk of carotid artery plaque in type 2 diabetes.

[0021] Use of Meteorin-like protein in obtaining markers for predicting the risk of carotid artery plaque occurrence in type 2 diabetes.

[0022] Use of Meteorin-like protein in the preparation of a product for predicting the risk of carotid artery plaque occurrence in type 2 diabetes.

[0023] The product includes a kit, or an in vitro diagnostic system or device.

[0024] The product is a kit, which at least includes a reagent for detecting a marker for predicting the risk of carotid artery plaque in type 2 diabetes, and the marker is a Meteorin-like protein.

[0025] If the serum level of Meteorin-like protein in the subject's sample is significantly increased compared with samples of type 2 diabetes without carotid artery plaques, it is judged that the subject has a high risk of developing type 2 diabetes combined with carotid artery plaques.

[0026] The following is a specific embodiment of the present invention:

[0027] 1. Collection of basic information

[0028] All subjects were asked in detail, and their personal information including name, gender, age, etc. were recorded. The subjects were asked whether they had diabetes and whether they were using hypoglycemic drugs. The subjects were asked whether they had hypertension and whether they were using antihypertensive drugs. The subjects were asked whether they had hyperlipidemia and whether they were using lipid-lowering drugs. At the same time, a special person was arranged to measure height, weight, neck circumference, waist circumference and hip circumference according to unified standards. Before measuring blood pressure, it was forbidden to eat irritating food. In a room with suitable temperature and quietness, the subjects were asked to sit and rest for about 15 minutes. Then the middle of the cuff was aligned with the heart level for measurement. The first beat sound heard by the stethoscope was the systolic pressure. The mercury column continued to rise by about 20 mmHg, and then the diastolic pressure was heard when the air was slowly deflated and stopped suddenly. Each measurement was 1 to 2 minutes apart. The blood pressure was measured three times in a row and the average value was taken. The relevant calculation formulas were: body mass index (BMI) = weight (kg) / height (m)^2; waist-hip ratio (WHR) = waist circumference / hip circumference. Weight was in kg and height was in m. Waist and hip circumference are measured in cm.

[0029] 2. Specimen collection

[0030] All subjects were fasting and drinking water after dinner the day before, and blood samples were collected on an empty stomach the next morning. The blood samples were then centrifuged using a desktop centrifuge (3000 rpm, 15 minutes), and an appropriate amount of blood sample supernatant was obtained and dispensed into 1.5 mL EP tubes. The dispensed blood samples were stored in a -80°C low-temperature refrigerator for future use.

[0031] 3. Testing of laboratory related indicators

[0032] (1) Oral glucose tolerance test

[0033] All subjects were required to undergo an oral glucose tolerance test and fast for at least 8 hours before the start of the test. The next morning, fasting blood samples were drawn from the sitting position, and 75g of anhydrous glucose was added to 250ml of water and drunk within 5 minutes. Blood samples were then drawn once at 30 minutes, 60 minutes, 120 minutes, and 180 minutes to measure blood glucose and insulin concentrations.

[0034] (2) Blood biochemical index detection

[0035] The present invention measures a variety of blood biochemical indicators: fast C-peptide (FC-P) is measured by radioimmunoassay; fast insulin (FIns) is measured by chemiluminescent immunoassay; glycosylated hemoglobinA1c (HbA1c) is measured by high performance liquid chromatography; fasting plasma glucose (FPG) is measured by glucose oxidase method; high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN) are measured by enzyme method; blood uric acid (UA) is measured by automatic biochemical analyzer. Professional personnel of the applicant's laboratory test department test and quality control the above data. Related calculation formulas: Homeostasis model insulin resistance index, HOMA-IR = FPG × FIns / 22.5; Homeostasis model pancreatic β-cell function index HOMA-β = FIns × 20 / (FPG-3.5). FPG is in mmol / L, FIns is in uIU / mL, triglyceride-glucose product index (TyG), TyG = ln[TG × FBG / 2], TG, FBG are in mg / dL.

[0036] (3) Determination of human serum Metrnl levels

[0037] Enzyme-linked immunosorbent assay (ELISA) was used to detect Metrnl levels in serum specimens. The Metrnl ELISA kit was purchased from Wuhan Huamei Biological Company, with an inter-batch CV ≤ 10% and an intra-batch CV ≤ 8%. The day before the experiment, the samples to be tested were moved from a -80°C refrigerator to a -20°C refrigerator overnight, and they needed to be equilibrated to room temperature when tested on the second day. All reagents were taken out and placed at room temperature for 30 to 60 minutes, and the reagents were prepared according to the above steps. There were 1 blank well, 7 standard wells, and wells for the samples to be tested. Slowly draw 100 μl of the standards of different concentrations with a 200 μl pipette and add them to the 7 standard wells in sequence. Add 100 μl of sample diluent to the blank well, and add 100 μl of the corresponding sample to be tested to each of the remaining wells. Gently shake to mix, and after the ELISA plate is coated, place it in a 37°C water bath and incubate for 120 minutes. Discard the liquid in each well, turn it upside down on absorbent paper and pat it dry without washing. Use a 200μl pipette to draw 100μl of biotin-labeled antibody working solution and add it to each well, shake gently to mix, cover with a new plate sticker, and incubate in a 37℃ water bath for 60 minutes. Discard the liquid in the well, and use the same method as above. Quickly wash the plate 3 times with washing working solution, soak and wash for 1 to 2 minutes each time and then discard the liquid, 200μl / well, and spin dry. Use a 200μl pipette to draw 100μl of horseradish peroxidase-labeled avidin working solution and add it to each well, then cover with a new plate sticker and incubate in a 37℃ water bath for 60 minutes. After incubation, quickly discard the liquid in the well and wash the plate 5 times. Use a 200μl pipette to draw 90μL of substrate solution and add it to each well, and place it in a dark place at 37℃ for color development for 15 to 30 minutes. Use a 100 μl pipette to draw 50 μL of stop solution and add it to each well. The solution turns yellow, indicating that the reaction is terminated. Use an enzyme reader to measure the OD value of each well at a wavelength of 450 nm.

[0038] Calculate sample concentration: The measured OD value is set as the horizontal axis, and the standard concentration is set as the vertical axis. Draw the standard curve and select the curve equation with the best fit. Substitute the OD value of the sample well into the curve equation to calculate the actual concentration value of the sample.

[0039] (4) Carotid artery ultrasound examination

[0040] In the applicant's ultrasound examination room, ultrasound professionals use color Doppler ultrasound diagnostic equipment to measure CIMT of all subjects to be tested (measure the vertical distance from the inner membrane of the blood vessel wall to the interface between the middle membrane and the outer membrane), and observe whether there are plaques in the patient's carotid artery (in the present invention, carotid plaque is defined as a local bulge that protrudes from the arterial lumen >0.5mm or exceeds 50% of the surrounding CIMT value or CIMT>1.5mm). The patient breathes calmly and needs to lie flat with the head facing the opposite side to ensure that the neck is exposed. Using a color Doppler ultrasound diagnostic instrument, place the ultrasound probe on the front or rear edge of the sternocleidomastoid muscle behind the mandibular angle of the neck, and move gradually to observe the condition of various parts of the carotid artery. Check the smoothness of the inner membrane, the clarity of the structure, and whether there is plaque formation. If a plaque is found, measure the size of the plaque. Measure 1 cm below the enlargement of the left and right carotid arteries 3 times, and take the average value as the final result of CIMT.

[0041] (5) Statistical analysis

[0042] SPSS 26.0 software was used for statistical analysis. Data that conformed to normal distribution were described using mean ± standard deviation (x ± SD); data that did not conform to normal distribution were described using median and interquartile range [M (Q25, Q75)]. For the quantitative data that conformed to normal distribution, the independent sample t test was used for comparison between the two groups, and the one-way analysis of variance was used for comparison between multiple groups; when the data did not conform to normal distribution, the nonparametric test was used for comparison between the two groups, and the Kruskalwallis test was used for comparison between multiple groups; Spearman was used to study the correlation between serum Metrnl levels and biochemical and clinical indicators; serum Metrnl levels were divided into tertiles from low to high, and all indicators of the subjects to be tested were compared; CIMT was set as the dependent variable, and multivariate stepwise regression analysis was used to explore the influencing factors of CIMT; whether T2DM patients had carotid plaques was set as the dependent variable (yes = 1, no = 0), and binary logistic regression analysis was used to explore the influencing factors of carotid plaques in T2DM patients; ROC curve was used to evaluate the value of serum Metrnl levels in predicting the occurrence of carotid plaques in T2DM patients. P < 0.05 (two-tailed) was considered statistically significant.

[0043] 1. Comparison of serum metrnl levels between normal control group and T2DM group

[0044] Compared with the normal control group, the metrnl level in the T2DM group (see Figure 1 ) were significantly increased, and the difference was statistically significant (P<0.05).

[0045] 2. Comparison of serum Metrnl levels between T2DM subjects with and without carotid artery plaques

[0046] The T2DM group was further divided into the T2DM group without carotid plaques and the T2DM group with carotid plaques. Compared with the T2DM group without carotid plaques, the serum Metrnl level in the T2DM group with carotid plaques was significantly increased (0.316 (0.171, 0.562) ng / ml) vs. (0.650 (0.336, 1.112) ng / ml), and the difference was statistically significant (P<0.05), see Figure 2 .

[0047] 3. Correlation analysis between serum Metrnl levels and various indicators

[0048] Correlation analysis between Metrnl and various indicators showed that serum Metrnl levels were positively correlated with age, systolic blood pressure, TG, UACR, FPG, 2hPG, Hb1Ac, HOMA-IR, and TyG in all subjects (r values ​​were 0.408, 0.150, 0.149, 0.225, 0.137, 0.174, 0.188, 0.148, and 0.175, respectively, P<0.05); no significant correlation was found between Metrnl and clinical indicators in normal subjects; in T2DM patients, Metrnl was positively correlated with age and CIMT (r values ​​were 0.394 and 0.270, respectively, P<0.05), as shown in Table 3.

[0049] Table 1 Correlation analysis between serum Metrnl and clinical indicators

[0050]

[0051]

[0052] Note: Normally distributed data are presented as mean ± standard deviation The data for non-normal distribution are expressed as median and interquartile range [M(Q25, Q75); BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: urea nitrogen; UA: uric acid; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; UACR: urine albumin-creatinine ratio; FPG: fasting plasma glucose; 2hPG: 2-hour postprandial plasma glucose; HbA1c: glycosylated hemoglobin; FIns: fasting insulin; 2hIns: 2-hour postprandial insulin; FC-P: fasting C-peptide; 2hC-P: 2-hour postprandial C-peptide; HOMA-IR: islet resistance index assessed by homeostasis model; HOMA-β: islet β-cell function index assessed by homeostasis model; TyG: triglyceride-glucose index.

[0053] 4. Multivariate stepwise regression analysis of factors affecting CIMT

[0054] Multivariate stepwise regression analysis was performed with CIMT as the dependent variable and age, systolic blood pressure, WHR, Metrnl, TG, FPG, HOMA-IR as independent variables. The results showed that Metrnl, age, FPG, and systolic blood pressure were independent influencing factors of CIMT (β=0.049, 0.007, 0.011, 0.002, P<0.05), see Table 4.

[0055] Table 2 Multivariate stepwise regression analysis of influencing factors of CIMT in patients with T2DM

[0056]

[0057] Note: Abbreviations are the same as those in Table 3.1, β: unstandardized coefficient; SE: standard error; β′: standardized coefficient; CI: confidence interval.

[0058] 5. Binary Logistic Regression Analysis of Factors Influencing Carotid Artery Plaque Formation

[0059] To further study the correlation between serum Metrnl levels and carotid plaques, binary logistic regression analysis was performed with whether T2DM patients had carotid plaques as the dependent variable (yes = 1, no = 0). The results showed that after adjusting for age, duration of diabetes, BMI, waist circumference, systolic blood pressure, TG, and history of metabolic syndrome, serum Metrnl levels were still associated with carotid plaques, and serum Metrnl was a risk factor for carotid plaque formation, as shown in Table 5.

[0060] Table 3 Logistic regression analysis of related factors for carotid artery plaque formation

[0061]

[0062] Note: Abbreviations are the same as those in Table 3.1, β: partial regression coefficient; SE: standard error; OR: odds ratio; CI: confidence interval.

[0063] 6. The diagnostic value of serum Metrnl level for T2DM complicated with carotid artery plaque

[0064] ROC curve analysis was performed with whether T2DM patients had carotid plaque as the state variable (no carotid plaque group = 0, carotid plaque group = 1), and Metrnl level as the test variable. The results showed that the area under the ROC curve of serum Metrnl in predicting the occurrence of carotid plaque in T2DM patients was 0.724 (95% CI: 0.648-0.800), and the optimal cutoff value was 0.392 ng / ml. Figure 3 The sensitivity and specificity of predicting the occurrence of carotid artery plaque were 71.3% and 67.9%, respectively.

[0065] Through the above experiments, it can be seen that the serum level of the Meteorin-like protein (Metrnl) is significantly increased in T2DM patients, and the difference is statistically significant (P<0.05).

[0066] The serum level of the nickel-like protein (Metrnl) was higher in the T2DM group with carotid plaque than in the T2DM group without carotid plaque, and the difference was statistically significant (P<0.05).

[0067] As the serum level of Metrnl gradually increased, the age of the subjects and the thickness of the carotid intima-media gradually increased (P<0.05).

[0068] The serum level of Metrnl was positively correlated with age, systolic blood pressure, triglycerides, urine microalbumin-to-creatinine ratio, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, and insulin resistance index;

[0069] The results of multivariate stepwise regression analysis showed that the serum level of Metrnl, age, fasting blood glucose, and systolic blood pressure were independent influencing factors of carotid intima-media thickness.

[0070] After adjusting for multiple confounding factors, the level of Metrnl was still associated with carotid plaques, and serum Metrnl was a risk factor for carotid plaque formation in patients with T2DM.

[0071] The results of ROC curve analysis showed that the area under the ROC curve of Metrnl level in predicting the occurrence of carotid plaque in T2DM patients was 0.724 (95% CI: 0.648-0.800), and the optimal cutoff value was 0.392 ng / ml, with a sensitivity and specificity of 71.3% and 67.9% for predicting the occurrence of carotid plaque, respectively.

[0072] The present invention confirms through a series of experiments that elevated serum Metrnl in T2DM patients is a risk factor for carotid plaque formation, suggesting that Metrnl may be involved in the development of macrovascular lesions in T2DM patients and is a predictive indicator for carotid plaque formation in T2DM patients. Meteorin-like protein, as a marker for predicting the risk of carotid plaque occurrence in type 2 diabetes, has a good predictive value for T2DM patients with carotid plaques.

[0073] The present invention is not limited to the disclosed example embodiments, and the present invention will cover various modifications and equivalent changes within the scope described in the patent and the scope of the claims.

Claims

1. Use of Meteorin-like protein as a marker for obtaining information on the risk of carotid artery plaques in type 2 diabetes.

2. Use of Meteorin-like protein in the preparation of a product for predicting the risk of carotid artery plaque development in type 2 diabetes.

3. Use of the Meteorin-like protein according to claim 2 in the preparation of a product for predicting the risk of carotid artery plaque in type 2 diabetes, characterized in that: The product includes a kit, or an in vitro diagnostic system or device.

4. Use of the Meteorin-like protein according to claim 3 in the preparation of a product for predicting the risk of carotid artery plaque in type 2 diabetes, characterized in that: The product is a kit, which at least includes a reagent for detecting a marker for predicting the risk of carotid artery plaque in type 2 diabetes, and the marker is a Meteorin-like protein.

5. Use of the Meteorin-like protein according to any one of claims 2 to 4 in the preparation of a product for predicting the risk of carotid artery plaques in type 2 diabetes, characterized in that: If the serum level of Meteorin-like protein in the subject's sample is significantly increased compared with samples of type 2 diabetes without carotid artery plaques, it is judged that the subject has a high risk of developing type 2 diabetes combined with carotid artery plaques.